Dare Bioscience, Inc. (DARE): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of DARE were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No DARE insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
DARE short interest
Moderate short interest. 6.4% of DARE shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went up 25%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 986,092 DARE shares were sold short, 6.4% of the shares outstanding, down 13.8% from the report before. At the average daily volume of 162,380 shares, buying them all back would take about 6.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 986,092 | 6.45% | -14% | 162,380 | 6.1 |
| Oct 15, 2026 | 1.14M | 7.48% | +24% | 110,991 | 10.3 |
| Sep 30, 2026 | 922,037 | 6.03% | +7% | 299,426 | 3.1 |
| Sep 15, 2026 | 859,250 | 5.62% | -12% | 266,138 | 3.2 |
| Aug 31, 2026 | 976,672 | 6.39% | -16% | 716,556 | 1.4 |
| Aug 14, 2026 | 1.17M | 7.63% | +39% | 1.51M | 1.0 |
| Jul 31, 2026 | 839,798 | 5.77% | +40% | 258,219 | 3.2 |
| Jul 15, 2026 | 601,255 | 4.13% | -13% | 100,894 | 6.0 |
| Jun 30, 2026 | 691,070 | 4.75% | -3% | 172,956 | 4.0 |
| Jun 15, 2026 | 716,065 | 4.92% | -13% | 180,781 | 4.0 |
| May 29, 2026 | 824,914 | 5.67% | +4% | 322,769 | 2.6 |
| May 15, 2026 | 791,165 | 5.43% | +121% | 1.27M | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Dare Bioscience company events
Dare Bioscience filed 25 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Oct 2, 2026.
- Oct 2, 2026ListingDaré Bioscience, Inc. received a letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying Daré that, for the last 30 consecutive business days, the closing bid price for Daré’s common stock was below the minimum $1.00 per share requirement for continued listing on The… Filing
- Oct 1, 2026AnnouncementShared information with investors. Filing
- Sep 11, 2026RulesChanged its bylaws or articles. Filing
- Sep 9, 2026AnnouncementShared information with investors. Filing
- Aug 17, 2026AgreementDaré Bioscience, Inc. entered into a securities purchase agreement with certain institutional investors relating to the purchase and sale of (i) 4,085,687 shares of our common stock, (ii) pre-funded warrants to purchase up to an aggregate of 293,894 shares of our common stock, (iii) warrants to… Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jul 24, 2026AnnouncementShared information with investors. Filing
- Jul 17, 2026ListingDare Biosciences, Inc. was notified by the Listing Qualifications Staff of The Nasdaq Stock Market LLC that, because the Company’s Form 10-Q for the period ended March 31, 2026 reported stockholders’ equity of less than $2.5 million and, as of July 13, 2026, the Company did not meet the alternative… Filing
- Jul 13, 2026AnnouncementShared information with investors. Filing
- Jun 22, 2026AnnouncementShared information with investors. Filing
- Jun 12, 2026LeadershipAs reported in Item 5.07 below, at the 2026 annual meeting of stockholders of Daré Bioscience, Inc., our stockholders approved an amendment to the Daré Bioscience, Inc. 2022 Stock Incentive Plan to increase the number of shares available for issuance thereunder by 1,500,000. Filing
- May 18, 2026SharesSold new shares outside a public offering. Filing
- May 14, 2026ResultsReleased financial results. Filing
- May 7, 2026SharesSold new shares outside a public offering. Filing
- Apr 22, 2026AnnouncementShared information with investors. Filing
- Apr 20, 2026SharesSold new shares outside a public offering. Filing
- Apr 17, 2026LeadershipUnder its Restated Certificate of Incorporation, as amended, and Third Amended and Restated By-laws, as amended, the board of directors of Daré Bioscience, Inc., is divided into three classes, with one class of directors standing for election each year for a three-year term, and each class is to… Filing
- Apr 13, 2026SharesSold new shares outside a public offering. Filing
- Mar 26, 2026ResultsReleased financial results. Filing
- Mar 17, 2026SharesSold new shares outside a public offering. Filing
- Mar 9, 2026SharesSold new shares outside a public offering. Filing
- Mar 2, 2026AnnouncementShared information with investors. Filing
- Jan 29, 2026AnnouncementOf this report is incorporated by reference into this Item 3.02 to the extent such information is responsive to the disclosure requirements of Item 3.02 of Current Report on Form 8-K. Item 3.03 Material Modification to Rights of Security Holders. Filing
- Jan 6, 2026AnnouncementShared information with investors. Filing
- Dec 1, 2025AgreementEnded an important agreement. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Dare Bioscience financials
Famous investors that hold DARE
1 of the 50 well-known investors we track reported holding DARE in their latest 13F filing. The largest position is Ken Griffin's, worth $38.5K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 45,142 | $38.5K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named DARE in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Lind Global Fund III LP | 13G/A | 5.0% |
| Nov 16, 2026 | Lind Global Fund III LP | 13G/A | 5.0% |
Questions about Dare Bioscience, Inc. (DARE) stock
Are DARE insiders buying or selling?
No DARE insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in DARE?
As of Oct 30, 2026, 986,092 DARE shares were sold short, 6.4% of the shares outstanding, down 13.8% from the report before. At the average daily volume of 162,380 shares, buying them all back would take about 6.1 trading days (days to cover). See the history.
Which famous investors hold DARE?
1 of the 50 well-known investors we track reported DARE in their latest 13F filing, including Ken Griffin. The largest position is worth $38.5K. See all holders.
Executive pay
Dare Bioscience's chief executive was paid a total of $801K for the year ended Dec 31, 2025, down 11% from $898K the year before. In the last 12 months, Dare Bioscience's executives and directors bought no stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.